CIK细胞治疗妇科肿瘤的临床研究

目的观察细胞因子诱导的杀伤细胞（CIK细胞）体外细胞毒活性,并观察CIK细胞治疗妇科肿瘤的近期临床疗效、免疫学活性及副反应.方法共收录2007年7月至2010年3月22例妇科肿瘤患者进行CIK细胞治疗,其中卵巢癌11例,子宫癌11例.经标准治疗方案治疗的患者,取外周血分离单个核细胞（PBMC）,体外诱导出CIK细胞培养后,观察CIK细胞表型,用MTT法测体外细胞毒活性.所有患者均接受一定剂量的CIK细胞过继免疫治疗,观察其近期临床疗效、免疫反应、不良反应.结果当效靶比为16：1、8：1时,CIK细胞体外细胞毒活性杀伤率分别（82.33±9.35）%和（61.59±13.59）%.卵巢癌11例,近期疗效评价中,部分缓解4例,近期有效率为66.67%,疾病控制率为66.67%.子宫癌11例,近期疗效评价中,部分缓解6例,近期有效率为100%,无肿瘤进展时间为4～26个月,中位无肿瘤进展时间为13个月.与CIK细胞回输前相比,患者CD3＋、CD4＋、CD8＋均有明显的升高（P〈0.05）,这表示可以诱导患者产生特异性的免疫反应.22例患者在输注CIK过程中未出现不良反应.结论 CIK细胞对妇科肿瘤有较好的临床疗效.

CIK Cells Treatment of Gynecologic Tumor

Objective To observe cytokine-induced killer cells（CIK cells）cytotoxic activity in vitro,and to observe the short-term clinical efficacy,immunological activity and side effects of CIK cells in treating gynecologic tumor.Methods A total of 22 patients with gynecological malignancies were recorded with CIK cell therapy from July 2007 to March 2010,in which 11 cases were ovarian cancer,11 cases were uterine cancer.Peripheral blood mononuclear cells（PBMC）from patients with standard treatment protocols were induced to CIK cells in vitro,then phenotype of CIK cells were observed and cytotoxicity in vitro was measured by MTT method.All patients received a certain dose of CIK cells in adoptive immunotherapy and the recent clinical efficacy,immune response and adverse effects were observed.Results Cytotoxic activity of CIK cells in vitro anti-ratio was（82.33 ± 9.35）% and（61.59 ± 13.59）% respectively when the ratio of effector cell to target cell was 16：1and 8：1.In the recent clinical efficacy evaluation,4 of 11 cases of ovarian cancer were partial remission and recent effective ratio was 66.67%,the disease control rate was 66.67%.6 of 11 uterine cancer cases were partial remission and recent effective ratio was 100%.No tumor progressing period was 4 to 26 months and the median was 13 months.The cells surface markers CD3＋,CD4＋,CD8＋ of patient＇s PBMC had increased（P0.05） compared with that before transfusion,which meant patient＇s specific immune response was induced by CIK cells.No adverse reaction was observed during the infusion of CIK cells for the 22 patients.Conclusion CIK cells have good clinical efficacy for gynecological tumor.